Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rheumatology
•
Langerhans Cell Histiocytosis
•
Hematology
•
General Rheumatology
•
Dermatology
•
Pediatric Rheumatology
•
Oncology
How do you approach evaluation of Langerhans cell histiocytosis?
What clinical features should raise suspicion for this diagnosis?
Related Questions
When would you consider use of emapalumab for HLH/MAS?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
When using IV TNF inhibitors, do you follow levels to determine if the current dose is adequately treating the patient?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
How do you approach recurrent migratory superficial thrombophlebitis in a patient with a negative malignancy workup and low-titer anticardiolipin antibodies?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
What specific historical questions do you prioritize when evaluating hair loss to identify features suggestive of autoimmune or connective tissue disorders?
In a patient with SJIA who has been stable on Anakinra however is now planning to conceive or becomes pregnant, would you consider switching to Cimzia?
In an infant whose mother resumes TNF inhibitor therapy (e.g., adalimumab, infliximab, certolizumab) after delivery and is breastfeeding, do you recommend delaying live vaccinations?
How would you approach escalation of therapy in an adult patient with refractory Still’s disease and associated MAS/HLH (ferritin >100,000, transaminitis, DIC) despite high-dose steroids, high-dose anakinra, tocilizumab, and ruxolitinib?